Early interventional treatment with intranasal corticosteroids compared with postonset treatment in pollinosis

Takaya Higaki, Mitsuhiro Okano, Seiichiro Makihara, Tazuko Fujiwara, Takenori Haruna, Yohei Noda, Shin Kariya, Kazunori Nishizaki

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The usefulness of early interventional treatment (EIT) with intranasal corticosteroids (INSs) compared with postonset treatment (POT) has not been clarified. Objectives: To study the efficacy and safety of EIT with INSs compared with POT and placebo in Japanese cedar/cypress pollinosis. Methods: We designed a 3-armed, double-blinded, randomized, placebo-controlled trial. Patients received mometasone furoate nasal spray (EIT group: n = 25), placebo (n = 25), or 4 weeks of placebo followed by 8 weeks of mometasone (POT group: n = 25) for a 12-week period starting on February 1, 2011. The primary end point was the comparison of the total nasal symptom score (TNSS) among the 3 groups. Total ocular symptom score (TOSS), total naso-ocular symptom score (TSS), Allergic Rhinitis and Its Impact (ARIA) on Asthma classification, and safety were the main secondary end points. Results: The placebo and POT groups, but not the EIT group, had a significant exacerbation of TNSS and TOSS soon after the start of pollen counts being high on consecutive days. The 12-week mean TSS in the EIT group (score, 2.3) was significantly lower than in the placebo (5.0; P

Original languageEnglish
Pages (from-to)458-464
Number of pages7
JournalAnnals of Allergy, Asthma and Immunology
Volume109
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Seasonal Allergic Rhinitis
Adrenal Cortex Hormones
Mometasone Furoate
Placebos
Therapeutics
Nose
Cupressus
Cryptomeria
Nasal Sprays
Safety
Pollen
Asthma
Randomized Controlled Trials

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Early interventional treatment with intranasal corticosteroids compared with postonset treatment in pollinosis. / Higaki, Takaya; Okano, Mitsuhiro; Makihara, Seiichiro; Fujiwara, Tazuko; Haruna, Takenori; Noda, Yohei; Kariya, Shin; Nishizaki, Kazunori.

In: Annals of Allergy, Asthma and Immunology, Vol. 109, No. 6, 12.2012, p. 458-464.

Research output: Contribution to journalArticle

@article{4af7f51e843b4e7d853d5fe6d96e48b9,
title = "Early interventional treatment with intranasal corticosteroids compared with postonset treatment in pollinosis",
abstract = "Background: The usefulness of early interventional treatment (EIT) with intranasal corticosteroids (INSs) compared with postonset treatment (POT) has not been clarified. Objectives: To study the efficacy and safety of EIT with INSs compared with POT and placebo in Japanese cedar/cypress pollinosis. Methods: We designed a 3-armed, double-blinded, randomized, placebo-controlled trial. Patients received mometasone furoate nasal spray (EIT group: n = 25), placebo (n = 25), or 4 weeks of placebo followed by 8 weeks of mometasone (POT group: n = 25) for a 12-week period starting on February 1, 2011. The primary end point was the comparison of the total nasal symptom score (TNSS) among the 3 groups. Total ocular symptom score (TOSS), total naso-ocular symptom score (TSS), Allergic Rhinitis and Its Impact (ARIA) on Asthma classification, and safety were the main secondary end points. Results: The placebo and POT groups, but not the EIT group, had a significant exacerbation of TNSS and TOSS soon after the start of pollen counts being high on consecutive days. The 12-week mean TSS in the EIT group (score, 2.3) was significantly lower than in the placebo (5.0; P",
author = "Takaya Higaki and Mitsuhiro Okano and Seiichiro Makihara and Tazuko Fujiwara and Takenori Haruna and Yohei Noda and Shin Kariya and Kazunori Nishizaki",
year = "2012",
month = "12",
doi = "10.1016/j.anai.2012.08.016",
language = "English",
volume = "109",
pages = "458--464",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "6",

}

TY - JOUR

T1 - Early interventional treatment with intranasal corticosteroids compared with postonset treatment in pollinosis

AU - Higaki, Takaya

AU - Okano, Mitsuhiro

AU - Makihara, Seiichiro

AU - Fujiwara, Tazuko

AU - Haruna, Takenori

AU - Noda, Yohei

AU - Kariya, Shin

AU - Nishizaki, Kazunori

PY - 2012/12

Y1 - 2012/12

N2 - Background: The usefulness of early interventional treatment (EIT) with intranasal corticosteroids (INSs) compared with postonset treatment (POT) has not been clarified. Objectives: To study the efficacy and safety of EIT with INSs compared with POT and placebo in Japanese cedar/cypress pollinosis. Methods: We designed a 3-armed, double-blinded, randomized, placebo-controlled trial. Patients received mometasone furoate nasal spray (EIT group: n = 25), placebo (n = 25), or 4 weeks of placebo followed by 8 weeks of mometasone (POT group: n = 25) for a 12-week period starting on February 1, 2011. The primary end point was the comparison of the total nasal symptom score (TNSS) among the 3 groups. Total ocular symptom score (TOSS), total naso-ocular symptom score (TSS), Allergic Rhinitis and Its Impact (ARIA) on Asthma classification, and safety were the main secondary end points. Results: The placebo and POT groups, but not the EIT group, had a significant exacerbation of TNSS and TOSS soon after the start of pollen counts being high on consecutive days. The 12-week mean TSS in the EIT group (score, 2.3) was significantly lower than in the placebo (5.0; P

AB - Background: The usefulness of early interventional treatment (EIT) with intranasal corticosteroids (INSs) compared with postonset treatment (POT) has not been clarified. Objectives: To study the efficacy and safety of EIT with INSs compared with POT and placebo in Japanese cedar/cypress pollinosis. Methods: We designed a 3-armed, double-blinded, randomized, placebo-controlled trial. Patients received mometasone furoate nasal spray (EIT group: n = 25), placebo (n = 25), or 4 weeks of placebo followed by 8 weeks of mometasone (POT group: n = 25) for a 12-week period starting on February 1, 2011. The primary end point was the comparison of the total nasal symptom score (TNSS) among the 3 groups. Total ocular symptom score (TOSS), total naso-ocular symptom score (TSS), Allergic Rhinitis and Its Impact (ARIA) on Asthma classification, and safety were the main secondary end points. Results: The placebo and POT groups, but not the EIT group, had a significant exacerbation of TNSS and TOSS soon after the start of pollen counts being high on consecutive days. The 12-week mean TSS in the EIT group (score, 2.3) was significantly lower than in the placebo (5.0; P

UR - http://www.scopus.com/inward/record.url?scp=84869877426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869877426&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2012.08.016

DO - 10.1016/j.anai.2012.08.016

M3 - Article

C2 - 23176888

AN - SCOPUS:84869877426

VL - 109

SP - 458

EP - 464

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 6

ER -